-
1
-
-
0141482004
-
Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia
-
DOI 10.1182/blood-2003-03-0925
-
Kantarjian H, Gandhi V, Cortes J, et al. Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. Blood 2003;102:2379-86 (Pubitemid 37193573)
-
(2003)
Blood
, vol.102
, Issue.7
, pp. 2379-2386
-
-
Kantarjian, H.1
Gandhi, V.2
Cortes, J.3
Verstovsek, S.4
Du, M.5
Garcia-Manero, G.6
Giles, F.7
Faderl, S.8
O'Brien, S.9
Jeha, S.10
Davis, J.11
Shaked, Z.12
Craig, A.13
Keating, M.14
Plunkett, W.15
Freireich, E.J.16
-
2
-
-
52649154001
-
A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome
-
Faderl S, Ravandi F, Huang X, et al. A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood 2008;112:1638-45
-
(2008)
Blood
, vol.112
, pp. 1638-1645
-
-
Faderl, S.1
Ravandi, F.2
Huang, X.3
-
3
-
-
84886859143
-
Clofarabine doubles the response rate in older patients with acute myeloid leukemia but does not improve survival
-
Burnett AK, Russell NH, Hunter AE, et al. Clofarabine doubles the response rate in older patients with acute myeloid leukemia but does not improve survival. Blood 2013;122:1384-94
-
(2013)
Blood
, vol.122
, pp. 1384-1394
-
-
Burnett, A.K.1
Russell, N.H.2
Hunter, A.E.3
-
4
-
-
0037276433
-
Antitumor activity of 2-fluoro-2′-deoxyadenosine against tumors that express Escherichia coli purine nucleoside phosphorylase
-
DOI 10.1038/sj.cgt.7700520
-
Parker WB, Allan PW, Hassan AE, et al. Antitumor activity of 2-fluoro-2-deoxyadenosine against tumors that express Escherichia coli purine nucleoside phosphorylase. Cancer Gene Ther 2003;10:23-9 (Pubitemid 36222073)
-
(2003)
Cancer Gene Therapy
, vol.10
, Issue.1
, pp. 23-29
-
-
Parker, W.B.1
Allan, P.W.2
Hassan, A.E.A.3
Secrist III, J.A.4
Sorscher, E.J.5
Waud, W.R.6
-
5
-
-
0026533461
-
Oral antilymphocyte activity and induction of apoptosis by 2-chloro 2-arabino-fluoro-2 deoxyadenosine
-
Carson DA, Wasson DB, Esparza LM, et al. Oral antilymphocyte activity and induction of apoptosis by 2-chloro 2-arabino-fluoro-2 deoxyadenosine. Proc Natl Acad Sci USA 1992;89:2970-4
-
(1992)
Proc Natl Acad Sci USA
, vol.89
, pp. 2970-2974
-
-
Carson, D.A.1
Wasson, D.B.2
Esparza, L.M.3
-
6
-
-
0345466497
-
Biochemical pharmacology and resistance to 2-chloro-2'-arabinofluoro-2'- deoxyadenosine, a novel analogue of cladribine in human leukemic cells
-
Lotfi K, Mansson E, Spasokoukotskaja T, et al. Biochemical pharmacology and resistance to 2-chloro-2'-arabino-fluoro-2'deoxyadenosine, a novel analogue of cladribine in human leukemic cells. Clin Cancer Res 1999;5:2438-44 (Pubitemid 29437325)
-
(1999)
Clinical Cancer Research
, vol.5
, Issue.9
, pp. 2438-2444
-
-
Lotfi, K.1
Mansson, E.2
Spasokoukotskaja, T.3
Pettersson, B.4
Liliemark, J.5
Peterson, C.6
Eriksson, S.7
Albertioni, F.8
-
7
-
-
0029053894
-
Metabolism and actions of 2-chloro-9-(2-deoxy-2-fluoro-D- arabinofuranosyl) adenine in human lymphoblastoid cells
-
Xie C, Plunkett W. Metabolism and actions of 2-chloro-9-(2-deoxy-2- fluoro-D-arabinofuranosyl) adenine in human lymphoblastoid cells. Cancer Res 1995;55:2847-52
-
(1995)
Cancer Res
, vol.55
, pp. 2847-2852
-
-
Xie, C.1
Plunkett, W.2
-
9
-
-
33749263031
-
Discovery and development of clofarabine: A nucleoside analogue for treating cancer
-
DOI 10.1038/nrd2055, PII NRD2055
-
Bonate PL, Arthaud L, Cantrell WR Jr, et al. Discovery and development of clofarabine: a nucleoside analogue for treating cancer. Nat Rev Drug Discov 2006;5:855-63 (Pubitemid 44480539)
-
(2006)
Nature Reviews Drug Discovery
, vol.5
, Issue.10
, pp. 855-863
-
-
Bonate, P.L.1
Arthaud, L.2
Cantrell, W.R.3
Stephenson, K.4
Secrist, J.A.5
Weitman, S.6
-
10
-
-
30044450909
-
A comparison of the transportability, and its role in cytotoxicity, of clofarabine, cladribine, and fludarabine by recombinant human nucleoside transporters produced in three model expression systems
-
King KM, Damaraju VL, Vickers MF, et al. A comparison of the transportability, and its role in cytotoxicity, of clofarabine, cladribine, and fludarabine by recombinant human nucleoside transporters produced in three model expression systems. Mol Pharmacol 2006;69:34-53
-
(2006)
Mol Pharmacol
, vol.69
, pp. 34-53
-
-
King, K.M.1
Damaraju, V.L.2
Vickers, M.F.3
-
11
-
-
0029927229
-
Deoxynucleotide pool depletion and sustained inhibition of ribonucleotide reductase and DNA synthesis after treatment of human lymphoblastoid cells with 2-chloro-(2-deoxy-fluoro-beta-D-arabinofuranosyl) adenine
-
Xie KC, Plunkett W. Deoxynucleotide pool depletion and sustained inhibition of ribonucleotide reductase and DNA synthesis after treatment of human lymphoblastoid cells with 2-chloro-(2-deoxy-fluoro-beta-D- arabinofuranosyl) adenine. Cancer Res 1996;56:3030-7
-
(1996)
Cancer Res
, vol.56
, pp. 3030-3037
-
-
Xie, K.C.1
Plunkett, W.2
-
12
-
-
0025811415
-
Effects of 2-chloro-9-(2-deoxy-2-fluorobeta-D-arabinofuranosyl) adenine on K562 cellular metabolism and the inhibition of human ribonucleotide reductase and DNA polymerases by 5'-triphosphate
-
Parker WB, Shaddix SC, Chang CH, et al. Effects of 2-chloro-9-(2-deoxy-2- fluorobeta-D-arabinofuranosyl) adenine on K562 cellular metabolism and the inhibition of human ribonucleotide reductase and DNA polymerases by 5'-triphosphate. Cancer Res 1991;51:2386-94
-
(1991)
Cancer Res
, vol.51
, pp. 2386-2394
-
-
Parker, W.B.1
Shaddix, S.C.2
Chang, C.H.3
-
13
-
-
0033063791
-
Comparison of the mechanism of cytotoxicity of 2-chloro-9,(2-deoxy-2- fluoro-β-D-arabinofuranosyl)adenine, 2-chloro-9-(2-deoxy-2-fluoro-β-D- ribofuranosyl)adenine, and 2-chloro-9-(2-deoxy-2,2-difluoro-β-D- ribofuranosyl)adenine in CEM cells
-
Parker WB, Shaddix SC, Rose L, et al. Comparison of the mechanism of cytotoxicity of 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl) adenine, 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl) adenine, 2-chloro-9-(2-deoxy-2, 2-difluoro-beta-Dribofuranosyl) adenine in CEM cells. Mol Pharmacol 1999;55:515-20 (Pubitemid 29128108)
-
(1999)
Molecular Pharmacology
, vol.55
, Issue.3
, pp. 515-520
-
-
Parker, W.B.1
Shaddix, S.C.2
Rose, L.M.3
Shewach, D.S.4
Hertel, L.W.5
Secrist III, J.A.6
Montgomery, J.A.7
Bennett Jr., L.L.8
-
14
-
-
0023733094
-
Interaction of 2-halogenated dATP analogs (F, Cl, and Br) with human DNA polymerases DNA primase, and ribonucleotide reductase
-
Parker WB, Bapat AR, Shen JX, et al. Interaction of 2-halogenated dATP analogs (F, Cl, and Br) with human DNA polymerases, DNA primase, and ribonucleotide reductase. Mol Pharmacol 1988;34:485-91
-
(1988)
Mol Pharmacol
, vol.34
, pp. 485-491
-
-
Parker, W.B.1
Bapat, A.R.2
Shen, J.X.3
-
15
-
-
0034669944
-
Deoxyadenosine analogs induce programmed cell death in chronic lymphocytic leukemia cells by damaging the DNA and by directly affecting the mitochondria
-
Genini D, Adachi S, Chao Q, et al. Deoxyadenosine analogs induce programmed cell death in chronic lymphocytic leukemia cells by damaging the DNA and by directly affecting the mitochondria. Blood 2000;96:3537-43
-
(2000)
Blood
, vol.96
, pp. 3537-3543
-
-
Genini, D.1
Adachi, S.2
Chao, Q.3
-
16
-
-
35148887258
-
Clofarabine: Past, present, and future
-
DOI 10.1080/10428190701545644, PII 781351511
-
Kantarjian HM, Jeha S, Gandhi V, et al. Clofarabine: past, present, and future. Leuk Lymphoma 2007;48:1922-30 (Pubitemid 47542978)
-
(2007)
Leukemia and Lymphoma
, vol.48
, Issue.10
, pp. 1922-1930
-
-
Kantarjian, H.M.1
Jeha, S.2
Gandhi, V.3
Wess, M.4
Faderl, S.5
-
17
-
-
84892376441
-
Population pharmacokinetics of clofarabine and its metabolite 6-ketoclofarabine in adult and pediatric patients with cancer
-
Bonate PL, Cunningham CC, Gaynon P. Population pharmacokinetics of clofarabine and its metabolite 6-ketoclofarabine in adult and pediatric patients with cancer. Clin Cancer Res 2003;9:6335-42
-
(2003)
Clin Cancer Res
, vol.9
, pp. 6335-6342
-
-
Bonate, P.L.1
Cunningham, C.C.2
Gaynon, P.3
-
18
-
-
67650798203
-
Effect of clofarabine on lymphocyte populations in patients treated for solid tumors
-
abstract 21134
-
Cunningham C, Nemunaitis J, Senzer N, et al. Effect of clofarabine on lymphocyte populations in patients treated for solid tumors. J Clin Oncol 2007;25:abstract 21134
-
(2007)
J Clin Oncol
, vol.25
-
-
Cunningham, C.1
Nemunaitis, J.2
Senzer, N.3
-
19
-
-
70349771790
-
Mechanisms of anti-cancer action and pharmacology of clofarabine
-
Zhenchuk A, Lotfi K, Juliusson G, et al. Mechanisms of anti-cancer action and pharmacology of clofarabine. Biochem Pharmacol 2009;78:1351-9
-
(2009)
Biochem Pharmacol
, vol.78
, pp. 1351-1359
-
-
Zhenchuk, A.1
Lotfi, K.2
Juliusson, G.3
-
20
-
-
0037445122
-
Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers
-
DOI 10.1200/JCO.2003.04.031
-
Kantarjian H, Gandhi V, Kozuch P, et al. Phase I clinical and pharmacology study of clofarabine (CI-F-ara-A; 2 chloro-2-fluoro-deoxy-9-beta-D- arabinofuranosyladenine) in patients with solid and hematologic cancers. J Clin Oncol 2003;21: 1167-73 (Pubitemid 46594149)
-
(2003)
Journal of Clinical Oncology
, vol.21
, Issue.6
, pp. 1167-1173
-
-
Kantarjian, H.M.1
Gandhi, V.2
Kozuch, P.3
Faderl, S.4
Giles, F.5
Cortes, J.6
O'Brien, S.7
Ibrahim, N.8
Khuri, F.9
Du, M.10
Rios, M.B.11
Jeha, S.12
McLaughlin, P.13
Plunkett, W.14
Keating, M.15
-
21
-
-
0346963139
-
Pharmacokinetics and Pharmacodynamics of Plasma Clofarabine and Cellular Clofarabine Triphosphate in Patients with Acute Leukemias
-
Gandhi V, Kantarjian H, Faderl S, et al. Pharmacokinetics and pharmacodynamics of plasma clofarabine and cellular clofarabine triphosphate in patients with acute leukemias. Clin Cancer Res 2003;9:6335-42 (Pubitemid 38031817)
-
(2003)
Clinical Cancer Research
, vol.9
, Issue.17
, pp. 6335-6342
-
-
Gandhi, V.1
Kantarjian, H.2
Faderl, S.3
Bonate, P.4
Du, M.5
Ayres, M.6
Rios, M.B.7
Keating, M.J.8
Plunkett, W.9
-
22
-
-
9144222570
-
Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia
-
DOI 10.1182/blood-2003-06-2122
-
Jeha S, Gandhi V, Chan K, et al. Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia. Blood 2004;103:784-9 (Pubitemid 38129533)
-
(2004)
Blood
, vol.103
, Issue.3
, pp. 784-789
-
-
Jeha, S.1
Gandhi, V.2
Chan, K.W.3
McDonald, L.4
Ramirez, I.5
Madden, R.6
Rytting, M.7
Brandt, M.8
Keating, M.9
Plunkett, W.10
Kantarjian, H.11
-
23
-
-
33646337195
-
Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia
-
DOI 10.1200/JCO.2005.03.8554
-
Jeha S, Gaynon P, Razzouk B, et al. Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. J Clin Oncol 2006;24:1917-23 (Pubitemid 46638991)
-
(2006)
Journal of Clinical Oncology
, vol.24
, Issue.12
, pp. 1917-1923
-
-
Jeha, S.1
Gaynon, P.S.2
Razzouk, B.I.3
Franklin, J.4
Kadota, R.5
Shen, V.6
Luchtman-Jones, L.7
Rytting, M.8
Bomgaars, L.R.9
Rheingold, S.10
Ritchey, K.11
Albano, E.12
Arceci, R.J.13
Goldman, S.14
Griffin, T.15
Altman, A.16
Gordon, B.17
Steinherz, L.18
Weitman, S.19
Steinherz, P.20
more..
-
24
-
-
0032917771
-
Antitumor activity of 2-chloro-9-(2-deoxy-2-fluoro-β-D- arabinofuranosyl) adenine, a novel deoxyadenosine analog, against human colon tumor xenografts by oral administration
-
DOI 10.1007/s002800050889
-
Takahashi T, Kanaqawa J, Akinaga S, et al. Antitumor activity of 2-chloro-9-(2-deoxy-fluoro-beta-D-arabinofuranosyl) adenine, a novel deoxyadenosine analog m against human colon tumor xenografts by oral administration. Cancer Chemother Pharmacol 1999;43:233-40 (Pubitemid 29042492)
-
(1999)
Cancer Chemotherapy and Pharmacology
, vol.43
, Issue.3
, pp. 233-240
-
-
Takahashi, T.1
Kanazawa, J.2
Akinaga, S.3
Tamaoki, T.4
Okabe, M.5
-
25
-
-
0034057850
-
Preclinical antitumor activity of 2-chloro-9-(2-deoxy-2-fluoro-β-D- arabinofuranosyl)adenine (Cl-F-ara-A)
-
Waud WR, Schmid SM, Montgomery JA, et al. Preclinical antitumor activity of 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl) adenine (Cl-F-ara-A). Nucleosides Nucleotides Nucleic Acids 2000;19:447-60 (Pubitemid 30230053)
-
(2000)
Nucleosides, Nucleotides and Nucleic Acids
, vol.19
, Issue.1-2
, pp. 447-460
-
-
Waud, W.R.1
Schmid, S.M.2
Montgomery, J.A.3
Secrist III, J.A.4
-
26
-
-
0020992379
-
Metabolism of 9-β-D-arabinosyl-2-fluoroadenine-5'-phosphate by mice bearing P388 leukemia
-
Avramis VI, Plunkett W. Metabolism of 9-, 6-D-arabinosyl-2fluoroadenine- 41-phosphate by mice bearing P388 leukemia. Cancer Drug Deliv 1983;1:1-10 (Pubitemid 15188060)
-
(1983)
Cancer Drug Delivery
, vol.1
, Issue.1
, pp. 1-10
-
-
Avramis, V.I.1
Plunkett, W.2
-
27
-
-
66749161188
-
Oral and intravenous clofarabine for patients with myelodysplastic syndrome
-
abstract 222
-
Faderl S, Garcia-Manero G, Ravandi F, et al. Oral and intravenous clofarabine for patients with myelodysplastic syndrome. Blood 2008;112:abstract 222
-
(2008)
Blood
, vol.112
-
-
Faderl, S.1
Garcia-Manero, G.2
Ravandi, F.3
-
28
-
-
77954911871
-
Oral clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome
-
Faderl S, Garcia-Manero G, Estrov Z, et al. Oral clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome. J Clin Oncol 2010;28:2755-60
-
(2010)
J Clin Oncol
, vol.28
, pp. 2755-2760
-
-
Faderl, S.1
Garcia-Manero, G.2
Estrov, Z.3
-
29
-
-
0023854422
-
Modulation of arabinosylnucleoside metabolism by arabinosylnucleotides in human leukemia cells
-
Gandhi V, Plunkett W. Modulation of arabinosyl nucleoside metabolism by arabinosyl nucleotides in human leukemia cells. Cancer Res 1988;48:329-34 (Pubitemid 18045766)
-
(1988)
Cancer Research
, vol.48
, Issue.2
, pp. 329-334
-
-
Gandhi, V.1
Plunkett, W.2
-
30
-
-
0021847172
-
Pharmacologically directed ara-C therapy for refractory leukemia
-
Plunkett W, Iacoboni S, Estey E, et al. Pharmacologically directed ara-C therapy for refractory leukemia. Semin Oncol 1985;12:20-30 (Pubitemid 15063578)
-
(1985)
Seminars in Oncology
, vol.12
, Issue.2
, pp. 20-30
-
-
Plunkett, W.1
Iacoboni, S.2
Estey, E.3
-
31
-
-
0023470734
-
Variables predicting response to high dose cytosine arabinoside therapy in patients with refractory acute leukemia
-
Estey E, Plunkett W, Dixon D, et al. Variable predicting response to high-dose cytosine arabinoside therapy in patients with refractory acute leukemia. Leukemia 1987;1:580-3 (Pubitemid 18005688)
-
(1987)
Leukemia
, vol.1
, Issue.8
, pp. 580-583
-
-
Estey, E.1
Plunkett, W.2
Dixon, D.3
Keating, M.4
McCredie, K.5
Freireich, E.J.6
-
32
-
-
15044340106
-
Biochemical modulation of cytarabine triphosphate by clofarabine
-
DOI 10.1007/s00280-004-0906-y
-
Cooper T, Agus M, Nowak B, et al. Biochemical modulation of cytarabine triphosphate by clofarabine. Cancer Chemother Pharmacol 2005;55:361-8 (Pubitemid 40379260)
-
(2005)
Cancer Chemotherapy and Pharmacology
, vol.55
, Issue.4
, pp. 361-368
-
-
Cooper, T.1
Ayres, M.2
Nowak, B.3
Gandhi, V.4
-
33
-
-
0023470734
-
Variables predicting response to high dose cytosine arabinoside therapy in patients with refractory acute leukemia
-
Estey E, Plunkett W, Dixon D, et al. Variable predicting response to high-dose cytosine arabinoside therapy in patients with refractory acute leukemia. Leukemia 1987;1:580-3 (Pubitemid 18005688)
-
(1987)
Leukemia
, vol.1
, Issue.8
, pp. 580-583
-
-
Estey, E.1
Plunkett, W.2
Dixon, D.3
Keating, M.4
McCredie, K.5
Freireich, E.J.6
-
34
-
-
19944433802
-
Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias
-
DOI 10.1182/blood-2004-05-1933
-
Faderl S, Gandhi V, O'Brien S, et al. Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory leukemias. Blood 2005;105:940-7 (Pubitemid 40170859)
-
(2005)
Blood
, vol.105
, Issue.3
, pp. 940-947
-
-
Faderl, S.1
Gandhi, V.2
O'Brien, S.3
Bonate, P.4
Cortes, J.5
Estey, E.6
Beran, M.7
Wierda, W.8
Garcia-Manero, G.9
Ferrajoli, A.10
Estrov, Z.11
Giles, F.J.12
Du, M.13
Kwari, M.14
Keating, M.15
Plunkett, W.16
Kantarjian, H.17
-
35
-
-
18044372314
-
Clofarabine plus cytarabine combination is active in newly diagnosed patients ‡ age 50 with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS)
-
abstract 875
-
Faderl S, Gandhi V, Verstovsek S, et al. Clofarabine plus cytarabine combination is active in newly diagnosed patients ‡ age 50 with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Blood 2004;104:abstract 875
-
(2004)
Blood
, vol.104
-
-
Faderl, S.1
Gandhi, V.2
Verstovsek, S.3
-
36
-
-
80051992418
-
Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure
-
Prébet T, Gore SD, Esterni B, et al. Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure. J Clin Oncol 2011;29:3322-7
-
(2011)
J Clin Oncol
, vol.29
, pp. 3322-3327
-
-
Prébet, T.1
Gore, S.D.2
Esterni, B.3
-
37
-
-
77956862198
-
Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy
-
Jabbour E, Garcia-Manero G, Batty N, et al. Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy. Cancer 2010;116:3830-4
-
(2010)
Cancer
, vol.116
, pp. 3830-3834
-
-
Jabbour, E.1
Garcia-Manero, G.2
Batty, N.3
-
38
-
-
84892386420
-
Outcome of patients (pts) with low and intermediate-1 risk myelodysplastic syndrome (MDS) after hypomethylating agent (HMA) failure
-
abstract 388
-
Jabbour E, Garcia-Manero G, Xiao L, et al. Outcome of patients (pts) with low and intermediate-1 risk myelodysplastic syndrome (MDS) after hypomethylating agent (HMA) failure. Blood 2013;122:abstract 388
-
(2013)
Blood
, vol.122
-
-
Jabbour, E.1
Garcia-Manero, G.2
Xiao, L.3
-
39
-
-
78650039737
-
A phase II study of low dose intravenous clofarabine for elderly patients with myelodysplastic syndrome who have failed 5-azacytidine
-
Lim SH, McMahan J, Zhang J, et al. A phase II study of low dose intravenous clofarabine for elderly patients with myelodysplastic syndrome who have failed 5-azacytidine. Leuk Lymphoma 2010;51(12):2258-61
-
(2010)
Leuk Lymphoma
, vol.51
, Issue.12
, pp. 2258-2261
-
-
Lim, S.H.1
McMahan, J.2
Zhang, J.3
-
40
-
-
84892406300
-
Clofarabine plus low-dose cytarabine for the treatment of patients with higher-risk myelodysplastic syndrome (MDS) who have been relapsing after, or are refractory to, hypomethylator agent therapy
-
abstract 1525
-
Nazha A, Garcia-Manero G, Kantarjian HM, et al. Clofarabine plus low-dose cytarabine for the treatment of patients with higher-risk myelodysplastic syndrome (MDS) who have been relapsing after, or are refractory to, hypomethylator agent therapy. Blood 2013;122:abstract 1525
-
(2013)
Blood
, pp. 122
-
-
Nazha, A.1
Garcia-Manero, G.2
Kantarjian, H.M.3
-
41
-
-
84892423768
-
A novel clofarabine bridge strategy facilitates allogeneic transplantation in patients with relapsed/refractory leukemia and highrisk myelodysplastic syndromes
-
Locke F, Agarwal R, Kunnavakkam R, et al. A novel clofarabine bridge strategy facilitates allogeneic transplantation in patients with relapsed/refractory leukemia and highrisk myelodysplastic syndromes. Bone Marrow Transplant 2013;17:1-7
-
(2013)
Bone Marrow Transplant
, vol.17
, pp. 1-7
-
-
Locke, F.1
Agarwal, R.2
Kunnavakkam, R.3
|